STIM Form 4: Director RSU grant of 10,531; direct ownership 588,767

Rhea-AI Filing Summary

Neuronetics (STIM) reported an insider equity award on Form 4. A director acquired 10,531 shares of common stock on 10/20/2025 through a restricted stock unit award that vested immediately, elected in lieu of a cash retainer. The transaction was recorded at $0 per unit, consistent with RSU grants.

Following this transaction, the director’s beneficial ownership stands at 588,767 shares, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CASCELLA ROBERT

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,531	$0.00	--

Holdings After Transaction: Common Stock — 588,767 shares (Direct)

Footnotes (1)

1. Pursuant to the Issuer's non-employee directors compensation plan the Reporting Person elected to receive shares of the Issuer's Common Stock in lieu of a cash retainer. Represents a restricted stock unit ("RSU") award that vested immediately upon the grant. Each RSU represents a right to receive one share of the Issuer's common stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CASCELLA ROBERT

(Last) (First) (Middle)

C/O NEURONETICS, INC.

3222 PHEONIXVILLE PIKE

(Street)

MALVERN PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neuronetics, Inc. [ STIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/20/2025		A(1)		10,531(2)	A	$0(3)	588,767	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pursuant to the Issuer's non-employee directors compensation plan the Reporting Person elected to receive shares of the Issuer's Common Stock in lieu of a cash retainer.

2. Represents a restricted stock unit ("RSU") award that vested immediately upon the grant.

3. Each RSU represents a right to receive one share of the Issuer's common stock.

	/s/ Patrick Devine, as Attorney-in-Fact	10/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Neuronetics (STIM) disclose on this Form 4?

A director acquired 10,531 shares via an RSU award on 10/20/2025 that vested immediately and was elected in lieu of a cash retainer.

How many shares does the reporting person own after the transaction?

The reporting person beneficially owns 588,767 shares directly after the transaction.

What was the transaction price for the RSUs reported by STIM?

The Form 4 lists a price of $0 per unit for the RSU grant, which is typical for stock-based awards.

Why did the director receive shares instead of cash at Neuronetics (STIM)?

Per the non-employee director compensation plan, the director elected to receive common stock in lieu of a cash retainer.

Did the RSUs vest immediately for the STIM director?

Yes. The filing states the RSU award vested immediately upon grant.

How many shares did each RSU represent for STIM?

Each RSU represents the right to receive one share of Neuronetics’ common stock.